Rhode Island MPJE Practice Exam 2025 – Complete Study Guide

The maximum concentration of dihydrocodeinone allowed per dosage unit in Schedule III is indeed 15 mg. This classification is based on the regulatory framework established by the Controlled Substances Act, which aims to categorize substances according to their potential for abuse and medical use.

Dihydrocodeinone, a semi-synthetic opioid, is subject to specific dosage limits to help control the risk of potential misuse and addiction. Schedule III drugs are considered to have a lower potential for abuse compared to Schedule I and II substances, but they still require careful regulation. The limit of 15 mg per dosage unit reflects an effort to balance medical need for pain management with the need to mitigate risks associated with opioids.

Other options do not align with the established regulation for this specific substance in Schedule III. Each of those amounts exceeds the legal limit, which is why they would not be acceptable for classification under this schedule. The adherence to these regulations is essential for pharmacists and prescribers to ensure compliance with state and federal laws regarding controlled substances.